Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities [0.03%]
肿瘤中的三级淋巴器官：时空异质性、免疫调控和转化机遇
Shuxuan Deng,Yanjie Chen,Bin Song et al.
Shuxuan Deng et al.
Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that form in or in close proximity to tumors and other chronically inflamed tissues, where they serve as crucial sites for local antigen presentation, lymphocyte priming, a...
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies [0.03%]
克服抗体药物偶联物的抵抗：从机制见解到前沿策略
Kexun Zhou,Xinrui Liu,Hong Zhu
Kexun Zhou
Antibody-drug conjugates (ADCs) have revolutionized cancer therapy, but therapeutic resistance poses a significant barrier to sustained efficacy. Multiple mechanisms contribute to ADCs resistance, including drug efflux mediated by transport...
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy [0.03%]
靶向PSMA的CAR-巨噬细胞通过驱动代谢重组以增强前列腺癌免疫治疗
Yangli Xu,Duoli Xie,Chunhao Cao et al.
Yangli Xu et al.
Although chimeric antigen receptor (CAR)-T cells have demonstrated remarkable efficacy against hematologic malignancies, their effectiveness in solid tumors is limited by poor tumor infiltration and severe cytokine release syndrome (CRS). C...
The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: a multicenter cohort study [0.03%]
基于血浆cfDNA的肝细胞癌液体活检生物标志物的基因组及表观基因组异常多中心队列研究
Dezhen Guo,Ao Huang,Jianlong Sun et al.
Dezhen Guo et al.
Circulating tumor DNA (ctDNA) is a promising biomarker for early cancer detection; however, the optimal biomarker approach for early detection of hepatocellular carcinoma (HCC) remains unclear. Furthermore, current next-generation sequencin...
Multicenter Study
Journal of hematology & oncology. 2025 Oct 29;18(1):94. DOI:10.1186/s13045-025-01747-6 2025
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities [0.03%]
癌症中的神经免疫轴：从机制到治疗机遇
Chunyu Zhang,Xiangdong Guo,Peikun Liu et al.
Chunyu Zhang et al.
In recent years, neural mechanisms involved in tumor initiation, progression, and immune regulation have garnered growing attention, fueling the rapid advancement of the burgeoning interdisciplinary domain of neuro-oncology. As a central co...
Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? [0.03%]
嵌合抗原受体T细胞疗法在实体瘤中的挑战与局限性：为何仅限于血液系统恶性肿瘤？
Manh-Cuong Vo,Van-Dinh-Huan Tran,Van-Tan Nguyen et al.
Manh-Cuong Vo et al.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering a highly personalized and potent immunotherapeutic approach. To date, the U.S. Food and Drug Administration has approved...
Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution [0.03%]
近期CAR-MSCs的研究进展：细胞免疫治疗的新引擎
Ying Chen,Jing Li,Yingying Ma et al.
Ying Chen et al.
In recent years, the development of chimeric antigen receptor (CAR) technology has greatly promoted the progress of cellular immunotherapy. Among them, CAR-T cell therapy has shown remarkable clinical effects in the treatment of hematologic...
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies [0.03%]
克隆性血细胞增多的种族差异及其对血液系统恶性肿瘤的影响
Zijian Zhang,Chao Cheng
Zijian Zhang
Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for hematologic malignancies (HM), but its distribution and clinical implications across diverse ancestries remain poorly characterized. In this study, we investi...
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia [0.03%]
B细胞成熟抗原是急性髓系白血病免疫治疗的新靶点
Ashley Varkey,Manpreet Bariana,Mark Batistick et al.
Ashley Varkey et al.
B cell maturation antigen (BCMA) has emerged as a prominent immunotherapeutic target in multiple myeloma (MM) due to its restricted expression on MM cells, plasma cells and mature B cells, with minimal presence in other normal tissues. In t...
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies [0.03%]
基因组编辑的同种异体CAR-T细胞：癌症免疫疗法的下一代疗法
Jingchao Su,Yifei Zeng,Zhuojin Song et al.
Jingchao Su et al.
Chimeric Antigen Receptor T (CAR-T) cell therapy has revolutionized cancer immunotherapy, particularly in hematological malignancies. However, the clinical application of autologous CAR-T cells faces significant high cost and manufacturing ...